Orally administered dual-responsive insulin nanomedicine for diabetes and diabetic retinopathy
Scientists develop an oral dual‑responsive #nanocomplex reacting to #ROS and glucose, lowering glycemia, reducing #OxidativeStress and #inflammation, and delaying #DiabeticRetinopathy, highlighting promise for #OralInsulin #nanomedicine.
Nanotechnology Reviews: doi.org/10.1515/ntre...
Infographic showing the process of using genetics to predict response to oral insulin treatment for Stage 3 Type 1 diabetes prevention. It includes icons representing participants in a trial, responders and nonresponders to oral insulin, and a chart depicting the analysis of genetic differences.
Research has revealed that people with certain genetic traits are more likely to respond to oral insulin treatment for preventing clinical type 1 diabetes. #T1D #OralInsulin
Read here ➡️ doi.org/10.2337/dc25-2006
Once-daily, high-dose oral insulin can delay the onset of type 1 diabetes mellitus in children who are genetically at risk of the disease, a study published in The Lancet has revealed
#ukpharmacy #diabetes #oralinsulin
Can the development of #Type1Diabetes in children with increased genetic risk be prevented or delayed? The POInT trial found gene-dependent effects of #OralInsulin treatment, marking a step toward personalized prevention strategies: go.tum.de/316802
@helmholtzmunich.bsky.social
📷Rawpixel/iStock
New Milestone Towards Personalized Prevention of Type 1 Diabetes
Primary Oral Insulin Trial (POInT)
First Results Imply Personalized Strategies for the Future of Type 1 Diabetes
👉 Learn more: t1p.de/x3pq6
🔗 To the original publication: t1p.de/4x9qu
@tum.de @diabresearch-dzd.bsky.social
#typ1diabetes #prevention #GPPAD #OralInsulin #Insulin
